Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
133.7 USD | +1.26% | +1.46% | +1.44% |
Apr. 17 | Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test | MT |
Apr. 16 | Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development | MT |
Financials (USD)
Sales 2024 * | 2.21B | Sales 2025 * | 2.52B | Capitalization | 13.44B |
---|---|---|---|---|---|
Net income 2024 * | 490M | Net income 2025 * | 664M | EV / Sales 2024 * | 5.04 x |
Net cash position 2024 * | 2.3B | Net cash position 2025 * | 3.04B | EV / Sales 2025 * | 4.13 x |
P/E ratio 2024 * |
28.3
x | P/E ratio 2025 * |
21
x | Employees | 1,400 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.73% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | +1.26% | ||
1 week | +1.46% | ||
Current month | -3.09% | ||
1 month | -5.49% | ||
3 months | -4.39% | ||
6 months | +21.02% | ||
Current year | +1.44% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.65% | 215 M€ | +12.92% | - | |
3.81% | 1 M€ | 0.00% | - | |
1.85% | 8 M€ | -.--% | ||
1.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 133.7 | +1.26% | 575,067 |
24-04-19 | 132 | -0.41% | 556,303 |
24-04-18 | 132.5 | -0.52% | 586,541 |
24-04-17 | 133.2 | +0.18% | 571,093 |
24-04-16 | 133 | +0.95% | 1,033,219 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.44% | 13.44B | |
+2.49% | 96.73B | |
-0.26% | 21.31B | |
-16.61% | 21.21B | |
-5.34% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+21.29% | 10.98B | |
-21.79% | 8.56B | |
+12.82% | 8.12B |
- Stock Market
- Equities
- NBIX Stock